De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
Xiuchun Chen(Henan Cancer Hospital), Zhenzhen Liu(Jilin University), Miao Deng(Hangzhou Women’s Hospital), Xianfu Sun(Henan Cancer Hospital), Min Yan(Dalian Institute of Chemical Physics), Chengzheng Wang(Henan Cancer Hospital), Lianfang Li(Henan Cancer Hospital), Bo Chen(Jishan County People's Hospital), You-Wen He, Jianghua Qiao(Henan Cancer Hospital), Dechuang Jiao(Zhengzhou University), Ya Wei(Hainan University), Jennifer K Plichta(Duke University), Mingde Ma(Henan University Huaihe Hospital and Huaihe Clinical Institute), Yue-Qing Feng(Xinxiang Central Hospital), Chong-Jian Zhang(Henan Cancer Hospital), Zhen-Duo Lu(Henan Cancer Hospital)
Cited by 32
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Salivary exosomal miR-24-3p serves as a potential detective biomarker for oral squamous cell carcinoma screening
|Biomedicine & Pharmacotherapy|2019|200
Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals
|Cancer Medicine|2019|197
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
|Proceedings of the National Academy of Sciences|2014|167
Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer
|Journal of Controlled Release|2019|126